

Intas Pharmaceuticals | Private Company Profile

Highlights

TTM Total Revenue

\$2.60B

As of 31-Mar-2025



Last Deal Details

Undisclosed

Secondary Transaction - Private 01-Mar-2026

Total Raised to Date

\$201.24M

As of 01-Mar-2026

Employees

22000

As of 09-Feb-2026



Post Valuation

\$8.50B [£]

As of 10-Oct-2022

General Information

Description

Manufacturer of pharmaceutical products intended to serve healthcare providers and patients. The company specializes in generic drugs, biosimilars, active pharmaceutical ingredients, injectable medicines, and oral solid dosage formulations, thereby enabling the treatment of various therapeutic areas, including oncology, cardiovascular, diabetology, gastroenterology, and neurology.

Most Recent Financing Status (as of 16-Mar-2026)

Capital Group Private Markets sold a stake in the company to an undisclosed buyer in approximately March 2026. Previously, Temasek Holdings sold its 7.16% stake in the company to an undisclosed buyer.

Website	www.intaspharma.com	Year Founded	1976
Entity Types	Private Company Acquirer	Universes	M&A, Private Equity, Venture Capital
Also Known As	Intas	Employees	22,000
Legal Name	Intas Pharmaceuticals Ltd.		
Business Status	Profitable		
Ownership Status	Privately Held (backing)		
Financing Status	Private Equity-Backed		
LinkedIn URL	Intas Pharmaceuticals		

Industries, Verticals & Keywords

Primary PitchBook Industry	Verticals	Keywords	GECS Sector
Pharmaceuticals	Life Sciences	hematological disease	Healthcare
	Manufacturing	malignancies treatment	
	Oncology	oncology product	GECS Industry Group
Other PitchBook Industries		pharmaceutical chain	Drug Manufacturers
Drug Discovery		plasma fractionation	
		solid tumor	GECS Industry
		tumor treatment	Drug Manufacturers - General
SIC Codes			
(2834) Pharmaceutical preparations			

Contact Information

Primary Contact	Primary Office
Jayesh Shah	Corporate House, Near Sola Bridge
Chief Financial Officer	S. G. Highway, Thaltej
jayesh@intaspharma.com	Ahmedabad, Gujarat 380054
Phone: +91 (0)79 6157 7000	India
	Phone: +91 (0)79 6157 7000
	generalqueries@intaspharma.com

Financials

Key Metrics	Fiscal Year 2023 End: 31-Mar-2023	Fiscal Year 2025 End: 31-Mar-2025	12 Months Ending Mar 2025 Start: 31-Mar-2024 End: 31-Mar-2025
Amounts in thousands, USD (except Ratios, Multiples & per share items)			
Income Statement			
Total Revenue	1,551,084	2,600,000	2,600,000
Revenue % Growth	-10.41%		
Gross Profit	1,111,126		
Gross Margin	+71.64%		
Balance Sheet			
Total Assets	2,321,687		

Top 5 Similar Companies

#	Name	Competitor	Financing Status	HQ Location	Primary Industry	Year Founded	Last Financing Date/Type	Last Financing Amount
1	Dr. Reddy's	✓	Corporation	Hyderabad, India	Pharmaceuticals	1984	2ndary - Open	
2	Cipla	✓	Corporation	Mumbai, India	Pharmaceuticals	1935		
3	Aurobindo Pharma		Corporation	Hyderabad, India	Pharmaceuticals	1986	2015/PIPE	\$350.00M
4	Sun Pharmaceutical Industries	✓	Corporation	Mumbai, India	Pharmaceuticals	1983	2016/Repurchase	\$101.17M
5	Lupin	✓	Corporation	Mumbai, India	Pharmaceuticals	1968	2023/PIPE	\$25.00M

Comparisons

	 Intas Pharmaceuticals	 Lupin	 Aurobindo Pharma	 Zydus Lifesciences
Description	Manufacturer of pharmaceutical products intended to serve healthcare providers and patients.	Manufacturer of pharmaceutical products based in Mumbai, India.	Manufacturer of pharmaceuticals based in Hyderabad, India.	Developer of pharmaceutical products intended to serve the complete spectrum of the pharmaceutical value chain.
Primary Industry	Pharmaceuticals	Pharmaceuticals	Pharmaceuticals	Pharmaceuticals
HQ Location	Ahmedabad, India	Mumbai, India	Hyderabad, India	Ahmedabad, India
Employees	22000 2026	24006 2025	40750 2025	27917 2025

	 Intas Pharmaceuticals	 Lupin	 Aurobindo Pharma	 Zydus Lifesciences
Total Raised	\$201.24M	\$55.00M	\$350.00M	\$85.42M
Post Valuation	\$8.50B ^E 10-Oct-2022	\$1.41B ^E 23-May-2009	\$935.98M 07-Jun-2007	\$515.67M ^E 27-Apr-2000
Last Financing Details	Undisclosed amount 2026/Secondary Transaction - Private	\$25.00M 2023/PIPE	\$350.00M 2015/PIPE	Undisclosed amount PIPE

^E Estimated

Patents

98

Total Patents
Families

338

Total Documents
Applications and Grants

100

Active

71

Pending

8

Expiring
In next 12 mo

167


Inactive

Top Patent Technology (CPC codes): Acyclic or carbocyclic compounds, Heterocyclic compounds, Peptides, Preparations for medical, dental or toiletry purposes, Steroids

Portfolio Breakdown



Each of the company's patent is represented once by it's earliest filing date and it's representative technology classification

Patent Technology: CPC Section




- Chemistry
- Human necessities
- No CPC Data

Patent Technology: CPC Class



Patent Technology: CPC Subclass



- Acyclic or carbocyclic compounds
- Enzymes
- Heterocyclic compounds
- No CPC Data
- Peptides
- Preparations for medical, dental or toiletry purposes
- Specific therapeutic activity of chemical compounds or medicinal preparations

Citations

Citations are defined as the number of unique patents that have made reference to the company's patent. Citations are often used as a signal of patent value.

Most Cited Patents: All Years

#	Patent Title	Forward Citations
1	Liquid pharmaceutical composition of adalimumab	32
2	Bilayer pharmaceutical composition for the treatment of obesity	28
3	Endoxifen citrate polymorph and process for preparing the same	26
4	Cloning, expression & purification method for the preparation of ranibizumab	20
5	Stabilizing paclitaxel potency by exposing the mixture to the gas oxygen causing acidification; antitumor agents, anticarcinogenic agents	19

Citations: Cites Intas Pharmaceuticals

Company	Forward Citations	Total Active & Pending Patents
 Amryt Pharma	24	122
 Akouos	14	130
 Fresenius Kabi	11	1,827
 Sanovel	10	437
 Atossa Therapeutics	9	156

Recent Patent Activity

Publication ID	Patent Title	Status	Activity Date	Publication Date	Technology (CPC)	Citations	Independent Claims	First Filing Date
EP-4678233-A2	Pharmaceutical composition comprising hmg-coa reductase inhibitors and fenofibrate	Pending	29-Apr-2026	14-Jan-2026	A61K31/505	12	1	31-Jul-2019
EP-4678233-A3	Pharmaceutical composition comprising hmg-coa reductase inhibitors and fenofibrate	Pending	29-Apr-2026	29-Apr-2026	A61K31/505	1		31-Jul-2019
EP-4115879-A1	Pharmaceutical composition comprising hmg-coa reductase inhibitors and fenofibrate	Active	24-Apr-2026	11-Jan-2023	A61P3/06	13	2	31-Jul-2019
EP-4115879-B1	Pharmaceutical composition comprising hmg-coa reductase inhibitors and fenofibrate	Active	24-Apr-2026	03-Dec-2025	A61K31/505		1	31-Jul-2019
EP-4504748-A1	Multi-component buffer system for purification of antibodies	Pending	22-Apr-2026	12-Feb-2025	C07K1/18			04-Apr-2022

Clinical Trials

Clinical Pipeline (1)

Last Updated: Within the last 5 years

Status: Active

Entity's Role: Show all

INTERVENTIONAL TRIALS

Early Phase 1	Phase 1	Phase 1 / Phase 2	Phase 2	Phase 2 / Phase 3	Phase 3	Phase 4	Without Phases
0	0	0	0	0	1	0	0
OBSERVATIONAL TRIALS		EXPANDED ACCESS					
Observational		Expanded Access					
0		0					

Recently Updated Clinical Trials

Trial Name	Phase	Disease or Condition	Drug/Intervention	Start Date	Last Updated	Status
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients	Phase 3	Triple Negative Breast Cancer	Drug: Nanosomal Docetaxel Lipid Suspension (100 Mg/m2); Drug: Nanosomal Docetaxel Lipid Suspension (75 Mg/m2); Drug: Taxotere® (100 Mg/m2)	10-Jul-2018 (Actual)	21-Mar-2025	Recruiting
Comparative Immunogenicity Study of Multiple Doses of Proposed Pegfilgrastim Biosimilar, INTP5 of Intas Pharmaceuticals Ltd., India Against Neulasta of Amgen Inc., USA in Healthy, Adult Human Subjects.	Phase 1	Healthy Volunteers; Immunogenicity	Combination Product: Intp5; Combination Product: Us Neulasta	26-Feb-2018 (Actual)	04-Oct-2019	Completed
Comparative, Pharmacokinetic and Pharmacodynamic Study of Subcutaneous Injections of INTP5 of Intas Pharmaceuticals Ltd., India Against Neulasta of Amgen Inc., USA in Healthy, Adult Human Subjects.	Phase 1	Pharmacokinetic Bioequivalence Study In Human Healthy Volunteers	Combination Product: Intp5; Combination Product: Us Neulasta	12-Feb-2018 (Actual)	04-Oct-2019	Completed

Current Team (9)

Name	Title	Board Seats	Office	Phone	Email
Nimish Chudgar	Chief Executive Officer & Managing Director		Ahmedabad, India	+91 (0)79 6157 7000	nimish_chudgar@intaspharma.com
Abhimanyu Ojha	Chief Financial Officer		Ahmedabad, India	+91 (0)79 6157 7000	
Jayesh Shah	Chief Financial Officer		Ahmedabad, India	+91 (0)79 6157 7000	jayesh@intaspharma.com
Kirti Maheshwari	Chief Operating Officer		Ahmedabad, India	+91 (0)79 6157 7000	kmaheshwari@intaspharma.com
Binish Chudgar	Executive Chairman & Managing Director	2	Ahmedabad, India	+91 (0)79 6157 7000	binish_chudgar@intaspharma.com
Urmish Chudgar	Managing Director	1	Ahmedabad, India	+91 (0)79 6157 7000	urmish_chudgar@intaspharma.com
Hasmukh Chudgar	Founder & Board Member	1	Ahmedabad, India	+91 (0)79 6157 7000	
Amit Arora	Senior Vice President & Head, CVS Cluster -1		Ahmedabad, India	+91 (0)79 6157 7000	amit_arora@intaspharma.com
Jitesh Laddha	Vice President of Merger and Acquisitions		Ahmedabad, India	+91 (0)79 6157 7000	jitesh_laddha@intaspharma.com

Current Board Members (7)

Name	Title	Representing	Role	Since	Phone	Email
Binish Chudgar	Executive Chairman & Managing Director	Intas Pharmaceuticals	Executive Chairman & Managing Director		+91 (0)79 6157 7000	binish_chudgar@intaspharma.com
Hasmukh Chudgar	Founder & Board Member	Intas Pharmaceuticals	Founder & Board Member	Jan 1976	+91 (0)79 6157 7000	
Ratnasami Venkatesh	Board Member	Self	Board Member	Nov 2014	+91 (0)79 6157 7000	
Sanjay Kukreja	Partner & Chief Investment Officer	ChrysCapital	Board Member	May 2020	+91 (0)17 2412 6260	
Surender Kumar	Board Member	Self	Board Member		+91 (0)12 4364 7300	
Tilokchand Ostwal	Board Member	Self	Board Member	Mar 2011	+91 (0)11 4684 6700	
Urmish Chudgar	Managing Director	Intas Pharmaceuticals	Managing Director	Sep 1996	+91 (0)79 6157 7000	urmish_chudgar@intaspharma.com

Deal History (16)

Category: All Deals

#	Deal Type	Date	Amount	Raised to Date	Pre-Val	Post-Val	Status	Stage
16.	Secondary Transaction - Private	01-Mar-2026		\$201.24M			Completed	Profitable

#	Deal Type	Date	Amount	Raised to Date	Pre-Val	Post-Val	Status	Stage
15.	Secondary Transaction - Private			\$201.24M			Completed	Profitable
14.	Secondary Transaction - Private	10-Oct-2022	\$270.00M ^E	\$201.24M		\$8.50B ^E	Completed	Profitable
13.	PE Growth/Expansion	30-Apr-2020	\$132.00M	\$201.24M	\$4.12B	\$4.25B ^E	Completed	Profitable
12.	Secondary Transaction - Private	01-Aug-2018		\$69.24M			Completed	Profitable
11.	Secondary Transaction - Private	03-Apr-2017	\$107.00M	\$69.24M		\$3.57B ^E	Completed	Profitable
10.	PE Growth/Expansion	01-Mar-2017		\$69.24M			Completed	Profitable
9.	Secondary Transaction - Private	10-Nov-2014	\$146.74M	\$69.24M		\$1.44B ^E	Completed	Profitable
8.	PE Growth/Expansion	25-Apr-2012	\$58.35M	\$69.24M	\$1.14B	\$1.20B ^E	Completed	Profitable
7.	Secondary Transaction - Private	01-Oct-2010		\$10.89M			Completed	Profitable
6.	IPO	02-Jun-2010				\$24.02M ^E	Cancelled	Profitable
5.	PE Growth/Expansion	01-May-2010	\$10.00M ^E	\$10.89M			Completed	Profitable
4.	Secondary Transaction - Private	11-Oct-2007	\$10.00M	\$0.89M		\$854.70M ^E	Completed	Profitable
3.	PE Growth/Expansion	01-Jan-2005	\$0.89M	\$0.89M	\$91.25M	\$92.14M ^E	Completed	Generating Revenue
2.	Secondary Transaction - Private	01-Jan-2005	\$10.60M			\$92.14M ^E	Completed	Generating Revenue
1.	PE Growth/Expansion						Completed	Generating Revenue

† Indicates an Add-On
E Estimated

Deal #16: Secondary Transaction - Private, Completed; 01-Mar-2026

Deal Info

Deal Types	Secondary Transaction - Private
Deal Date	01-Mar-2026
Deal Status	Completed
Financing Source	Other

Company Info

Financing Status	Private Equity-Backed
Business Status	Profitable
CEO/Lead Mgt	Nimish Chudgar
Site	Ahmedabad, India

Total Capital

Raised to Date	\$201.24M **
-----------------------	--------------

Deal Synopsis

Capital Group Private Markets sold a stake in the company to an undisclosed buyer in approximately March 2026.

‡ Not necessarily a summation of individual debt figures

** Does not include grant funding

E Estimated

Sellers/Exiters (1)

#	Seller/Exiter Name	Partial/Full	Comments	
1.	Capital Group Private Markets	Full	% Company Still Held:	0.00%

E Estimated

Deal #15: Secondary Transaction - Private, Completed

Deal Info

Deal Types	Secondary Transaction - Private
Deal Status	Completed
Financing Source	Other

Company Info

Financing Status	Private Equity-Backed
Business Status	Profitable
CEO/Lead Mgt	Nimish Chudgar
Site	Ahmedabad, India

Total Capital

Raised to Date	\$201.24M **
-----------------------	--------------

Equity

% Acquired	7.16%
-------------------	-------

Deal Synopsis

Temasek Holdings sold its 7.16% stake in the company to an undisclosed buyer.

‡ Not necessarily a summation of individual debt figures

** Does not include grant funding

E Estimated

Sellers/Exiters (1)

#	Seller/Exiter Name	Partial/Full	Comments
1.	Temasek Holdings	Full	% Company Sold: 7.16% % Company Still Held: 0.00%

E Estimated

Stock Info

% Owned by Buyer Before 0.00%

% Owned by Buyer After 7.16%

E Shares Sought and Price Per Share calculated using the Weighted Average Method

Deal #14: Secondary Transaction - Private, \$270.00M, Completed; 10-Oct-2022

Deal Info

Deal Types Secondary Transaction - Private
Announced Date 26-Apr-2022
Deal Date 10-Oct-2022
Deal Status Completed
Financing Source Private Equity

Company Info

Financing Status Private Equity-Backed
Business Status Profitable
CEO/Lead Mgt Nimish Chudgar
Site Ahmedabad, India

Total Capital

Deal Amount \$270.00M^E
Post Valuation \$8.50B^E
Raised to Date \$201.24M^{**}

Equity

% Acquired 3.00%

Deal Synopsis

Temasek Holdings sold a 3% stake in the company to Abu Dhabi Investment Authority for an estimated \$270 million on October 10, 2022.

‡ Not necessarily a summation of individual debt figures

** Does not include grant funding

E Estimated

Investors (1)

Investor Name	Status	Lead/Sole	Comments	
1. Abu Dhabi Investment Authority	New Investor	No	Amount:	\$270.00M

E Estimated

Sellers/Exiters (1)

#	Seller/Exiter Name	Partial/Full	Comments	
1.	Temasek Holdings	Partial	Amount:	\$270.00M ^E
			% Company Sold:	3.00%
			% Company Still Held:	7.16%

E Estimated

Stock Info

% Owned by Buyer Before 0.00%**% Owned by Buyer After** 3.00%*E Shares Sought and Price Per Share calculated using the Weighted Average Method*

Deal #13: PE Growth/Expansion, \$132.00M, Completed; 30-Apr-2020

Deal Info

Deal Types	PE Growth/Expansion
Deal Date	30-Apr-2020
Deal Status	Completed
Financing Source	Private Equity

Company Info

Financing Status	Private Equity-Backed
Business Status	Profitable
CEO/Lead Mgt	Nimish Chudgar
Site	Ahmedabad, India

Total Capital

Deal Amount	\$132.00M
Pre-money Valuation	\$4.12B
Post Valuation	\$4.25B ^E
Total Invested Capital	\$132.00M
Raised to Date	\$201.24M **

Equity

% Acquired	3.00%
Total Invested Equity	\$132.00M

Deal Synopsis

The company received \$132 million of development capital from ChrysCapital on April 30, 2020. The transaction values the company at an estimated \$4.25 billion.

‡ Not necessarily a summation of individual debt figures

** Does not include grant funding

E Estimated

Investors (1)

Investor Name	Status	Lead/Sole	Comments
1. ChrysCapital	Follow-On Investor	No	Amount: \$132.00M Lead Partner: Sanjay Kukreja Form of Payment: Cash Fund 1: ChrysCapital VII

E Estimated

Advisors (1)

#	Advisor Name	Service Type	Hired By	Comments
1.	Shardul Amarchand Mangaldas & Company	Legal Advisor	ChrysCapital	

Stock Info

% Owned by Buyer Before 3.00%

% Owned by Buyer After 6.00%

E Shares Sought and Price Per Share calculated using the Weighted Average Method

Deal #12: Secondary Transaction - Private, Completed; 01-Aug-2018

Deal Info

Deal Types Secondary Transaction - Private
Deal Date 01-Aug-2018
Deal Status Completed
Financing Source Other

Company Info

Financing Status Private Equity-Backed
Business Status Profitable
CEO/Lead Mgt Nimish Chudgar
Site Ahmedabad, India

Total Capital

Raised to Date \$69.24M **

Deal Synopsis

Kotak Private Equity Group and The Capital Group Companies sold their stake in the company to an undisclosed buyer in approximately August 2018.

‡ Not necessarily a summation of individual debt figures

** Does not include grant funding

E Estimated

Sellers/Exiters (2)

#	Seller/Exiter Name	Partial/Full	Comments	
1.	Kotak Private Equity Group	Full	Fund 1: % Company Still Held:	Kotak India Venture Fund 0.00%
2.	The Capital Group Companies	Full	% Company Still Held:	0.00%

E Estimated

Investors (9)

Active Investors (2)

Name	Investor Type	Holding	Investor Since	Board	Related Deals
Abu Dhabi Investment Authority	Sovereign Wealth Fund	Minority	Oct 2022		#14. Secondary Transaction - Private: New Investor, Oct 2022, \$270.00M

Name	Investor Type	Holding	Investor Since	Board	Related Deals
ChrysCapital	PE/Buyout	Minority	Jan 2005	✓	#2. Secondary Transaction - Private: New Investor, Jan 2005, Sanjay Kukreja, \$10.60M #3. PE Growth/Expansion: Follow-on, Jan 2005, Sanjay Kukreja, \$0.89M #4. Secondary Transaction - Private: Seller, Oct 2007, \$10.00M #6. IPO: Seller, Jun 2010 #8. PE Growth/Expansion: Follow-on, Apr 2012, Sanjay Kukreja, \$58.35M #9. Secondary Transaction - Private: Seller, Nov 2014, \$146.74M #11. Secondary Transaction - Private: Seller, Apr 2017, \$107.00M #13. PE Growth/Expansion: Follow-on, Apr 2020, Sanjay Kukreja, \$132.00M

Former Investors (6)

Name	Investor Type	Holding	Investor Since	Board	Related Deals
The Capital Group Companies	Asset Manager	Minority	Apr 2017		#11. Secondary Transaction - Private: New Investor, Apr 2017, \$107.00M #12. Secondary Transaction - Private: Seller, Aug 2018
Capital Group Private Markets	PE/Buyout	Minority	Mar 2017		#10. PE Growth/Expansion: New Investor, Mar 2017 #16. Secondary Transaction - Private: Seller, Mar 2026
Temasek Holdings	Sovereign Wealth Fund	Minority	Nov 2014		#9. Secondary Transaction - Private: New Investor, Nov 2014, \$146.74M #14. Secondary Transaction - Private: Seller, Oct 2022, \$270.00M #15. Secondary Transaction - Private: Seller
Tata Capital	PE/Buyout	Minority	May 2010		#5. PE Growth/Expansion: New Investor, May 2010, Visalakshi Chandramouli, \$10.00M #7. Secondary Transaction - Private: Seller, Oct 2010

Name	Investor Type	Holding	Investor Since	Board	Related Deals
Kotak Private Equity Group	PE/Buyout	Minority	Oct 2007		#4. Secondary Transaction - Private: New Investor, Oct 2007, \$10.00M #12. Secondary Transaction - Private: Seller, Aug 2018
ICICI Venture	Asset Manager	Minority	Jan 2005		#1. PE Growth/Expansion: New Investor #2. Secondary Transaction - Private: Seller, Jan 2005, \$10.60M

Failed Investors (1)

Name	Investor Type	Related Deals
Eight Roads	Corporate Venture Capital	#6. IPO: New Investor, Jun 2010

Service Providers

General Service (1)

Service Provider Name	Service Provided	Comments
Vivro Financial Services	Advisor: General	End Date: 01-Jul-2018

Service on a Deal (5)

Service Provider Name	Service Provided	Service To	Deal Date	Deal #	Comments
Shardul Amarchand Mangaldas & Company	Legal Advisor	ChrysCapital	30-Apr-2020	13	
Debevoise & Plimpton	Legal Advisor	The Capital Group Companies	03-Apr-2017	11	
Moelis & Company	Advisor: General	ChrysCapital	03-Apr-2017	11	End Date: 03-Apr-2017
Khaitan & Company	Legal Advisor	Temasek Holdings	10-Nov-2014	9	
The Goldman Sachs Group	Advisor: General	Temasek Holdings	10-Nov-2014	9	End Date: 10-Nov-2014

Lead Partners on Deals (6)

Investors (5)

Name	All Deals	Title	Representing	Deals	Phone	Email
Sanjay Kukreja	22	Partner & Chief Investment Officer	ChrysCapital	#13. PE Growth/Expansion: Apr 2020, \$132.00M, Completed	+91 (0)17 2412 6260	
Sanjay Kukreja	22	Partner & Chief Investment Officer	ChrysCapital	#8. PE Growth/Expansion: Apr 2012, \$58.35M, Completed	+91 (0)17 2412 6260	
Visalakshi Chandramouli	9	Founding Partner & Managing Partner of Tata Capital Healthcare Fund	Tata Capital	#5. PE Growth/Expansion: May 2010, \$10.00M, Completed	+91 (0)22 6606 9000	visalakshi.c@tatacapital.com
Sanjay Kukreja	22	Partner & Chief Investment Officer	ChrysCapital	#3. PE Growth/Expansion: Jan 2005, \$0.89M, Completed	+91 (0)17 2412 6260	
Sanjay Kukreja	22	Partner & Chief Investment Officer	ChrysCapital	#2. Secondary Transaction - Private: Jan 2005, \$10.60M, Completed	+91 (0)17 2412 6260	

Service Providers - Buy Side (1)

Name	All Deals	Title	Representing	Deals	Phone	Email
William Chua JD	6	Partner	Debevoise & Plimpton	#11. Secondary Transaction - Private: Apr 2017, \$107.00M, Completed		

Investments | Buy Side (4)

Company Name	Deal Date	Deal Type	Deal Size	Co-Investors	Company Stage	Industry	Lead Partner
Prothya Biosolutions	20-Oct-2025	Buyout/LBO (Add-on) [†]		3	Generating Revenue	BPO/Outsource Services	Binish Chudgar
Udenyca	11-Apr-2025	Buyout/LBO [†]	\$483.40M	3		Buildings and Property	Binish Chudgar
RPG Life Sciences (Biotech Unit)	04-Oct-2016	Buyout/LBO (Add-on) [†]	\$3.75M	2	Profitable	Biotechnology	

Company Name	Deal Date	Deal Type	Deal Size	Co-Investors	Company Stage	Industry	Lead Partner
*Biologics Process Development	19-Jun-2008	Buyout/LBO (Add-on) [†]		2	Generating Revenue	Laboratory Services (Healthcare)	Dhananjay Patankar Ph.D
[†] Indicates an Add-On E Estimated x Investor Exited Deal							

Affiliates


Subsidiaries (1)

Name	Industry	Location	Year Founded
Prothya Biosolutions	BPO/Outsource Services	Amsterdam, Netherlands	2015

Signals

Referring Domains

1,170 total as of 25-Apr-2026



Last 10 News Articles

Title	Publisher	
Gemcitabine Hydrochloride Market Report 2026-2030 & 2035 Featuring Strategic Analysis of Fresenius Kabi, Eli Lilly and Company, Teva Pharma, Intas Pharma, Mylan and More	Company Press Release	01-Apr-2026 at 06:42 AM
Kashiv BioSciences and Intas Pharmaceuticals Sign an Exclusive Licensing and Supply Agreement for Complex Peptide Product in Eur...	Biospace	09-Feb-2026 at 20:00 PM

Title	Publisher	
Â© 2019 Intas Pharmaceuticals Ltd.	Company Press Release	04-Dec-2025 at 23:00 PM
Intas Pharmaceuticals	Company Press Release	07-Nov-2025 at 11:32 AM
Bio-Thera Solutions Announces Expansion of Partnership with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing...	Biospace	09-Oct-2025 at 20:00 PM
Bio-Thera Solutions Announces Expansion of Partnership with Intas Pharmaceuticals for BAT2506, A Proposed Biosimilar Referencing Simponi®, Through Exclusive Commercialization and License Agreement in Canada	Market Screener	09-Oct-2025 at 11:58 AM
Bio-Thera Solutions Announces Expansion of Partnership with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi® (golimumab), through Exclusive Commercialization and License Agreement in Canada	Company Press Release	08-Oct-2025 at 20:00 PM
Intas Pharma completes acquisition of UDENYCA biosimilar for \$558 million	Economic Times	13-Aug-2025 at 01:08 AM
Intas Pharmaceuticals and Accord BioPharma Become One of the Largest Global Suppliers of Pegfilgrastim with Acquisition of UDENYCA®	PR NewsWire	07-Aug-2025 at 01:00 AM
Accord Healthcare receives approval for Hetronify® (Serplulimab), from the Medicines and Healthcare Regulatory Agency (MHRA) for first-line treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)	PR NewsWire	24-Jun-2025 at 02:00 AM

Sourcing

Copyright © 2026 PitchBook Data, Inc. All rights reserved.
Provided under contract for the exclusive use of subscriber Jodi Nelson, Latham & Watkins.